These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 7501178)

  • 1. Vigabatrin edema.
    Cocito L; Maffini M
    Neurology; 1995 Nov; 45(11):2115-6. PubMed ID: 7501178
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of ex vivo magnetic resonance imaging to detect onset of vigabatrin-induced intramyelinic edema in canine brain.
    Peyster RG; Sussman NM; Hershey BL; Heydorn WE; Meyerson LR; Yarrington JT; Gibson JP
    Epilepsia; 1995 Jan; 36(1):93-100. PubMed ID: 8001516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MRI monitoring of vigabatrin-induced intramyelinic edema in dogs.
    Weiss KL; Schroeder CE; Kastin SJ; Gibson JP; Yarrington JT; Heydorn WE; McBride RG; Sussman NM; Arezzo JC
    Neurology; 1994 Oct; 44(10):1944-9. PubMed ID: 7936252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vigabatrin-induced optic neuropathy.
    Crofts K; Brennan R; Kearney P; O'Connor G
    J Neurol; 1997 Oct; 244(10):666-7. PubMed ID: 9402546
    [No Abstract]   [Full Text] [Related]  

  • 5. Vigabatrin and psychosis: is there a true correlation?
    Veggiotti P; De Agostini G; Baldi PL; Muzio C; Lanzi G
    Acta Neurol Scand; 1997 Mar; 95(3):189-90. PubMed ID: 9088390
    [No Abstract]   [Full Text] [Related]  

  • 6. Rapid aggravation of aphasia by vigabatrin.
    Gil R; Neau JP
    J Neurol; 1995 Mar; 242(4):251-2. PubMed ID: 7798126
    [No Abstract]   [Full Text] [Related]  

  • 7. Severe persistent visual field constriction associated with vigabatrin. Asymptomatic as well as symptomatic defects occur with vigabatrin.
    Mackenzie R; Klistorner A
    BMJ; 1998 Jan; 316(7126):233. PubMed ID: 9468717
    [No Abstract]   [Full Text] [Related]  

  • 8. Severe persistent visual field constriction associated with vigabatrin. Patients taking vigabatrin should have regular visual field testing.
    Blackwell N; Hayllar J; Kelly G
    BMJ; 1997 Jun; 314(7095):1694. PubMed ID: 9193313
    [No Abstract]   [Full Text] [Related]  

  • 9. Severe persistent visual field constriction associated with vigabatrin. Four possible explanations exist.
    Harding GF
    BMJ; 1997 Jun; 314(7095):1694. PubMed ID: 9193314
    [No Abstract]   [Full Text] [Related]  

  • 10. Focal lesion in the splenium of the corpus callosum in epileptic patients: antiepileptic drug toxicity?
    Tennison M
    AJNR Am J Neuroradiol; 1999 Jan; 20(1):131-2. PubMed ID: 10348730
    [No Abstract]   [Full Text] [Related]  

  • 11. Guideline may help in prescribing vigabatrin.
    Appleton RE
    BMJ; 1998 Nov; 317(7168):1322. PubMed ID: 9804738
    [No Abstract]   [Full Text] [Related]  

  • 12. [Acute psychosis and vigabatrin in childhood].
    Chiaretti A; Castorina M; Tortorolo L; Piastra M; Polidori G
    Pediatr Med Chir; 1994; 16(5):489-90. PubMed ID: 7885961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe persistent visual field constriction associated with vigabatrin. Manufacturers have started several studies.
    Backstrom JT; Hinkle RL; Flicker MR
    BMJ; 1997 Jun; 314(7095):1694-5. PubMed ID: 9193315
    [No Abstract]   [Full Text] [Related]  

  • 14. Vigabatrin overdose.
    Davie MB; Cook MJ; Ng C
    Med J Aust; 1996 Oct; 165(7):403. PubMed ID: 8890852
    [No Abstract]   [Full Text] [Related]  

  • 15. Vigabatrin aggravates absences and absence status.
    Panayiotopoulos CP; Agathonikou A; Sharoqi IA; Parker AP
    Neurology; 1997 Nov; 49(5):1467. PubMed ID: 9371946
    [No Abstract]   [Full Text] [Related]  

  • 16. Vigabatrin-associated retinal cone system dysfunction.
    Brigell MG
    Neurology; 1998 Dec; 51(6):1779-81. PubMed ID: 9855563
    [No Abstract]   [Full Text] [Related]  

  • 17. Vigabatrin-associated retinal cone system dysfunction.
    Roubertie A; Bellet H; Echenne B
    Neurology; 1998 Dec; 51(6):1779-81. PubMed ID: 9855564
    [No Abstract]   [Full Text] [Related]  

  • 18. Vigabatrin-associated retinal cone system dysfunction.
    Beck RW
    Neurology; 1998 Dec; 51(6):1778-9; author reply 1779-81. PubMed ID: 9855562
    [No Abstract]   [Full Text] [Related]  

  • 19. Severe persistent visual field constriction associated with vigabatrin. Benefit: risk ratio must be calculated for individual patients.
    Harding GF
    BMJ; 1998 Jan; 316(7126):232-3. PubMed ID: 9468716
    [No Abstract]   [Full Text] [Related]  

  • 20. Severe persistent visual field constriction associated with vigabatrin. Reaction might be dose dependent.
    Wong IC; Mawer GE; Sander JW
    BMJ; 1997 Jun; 314(7095):1693-4. PubMed ID: 9193312
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.